Patents Issued in January 12, 2010
  • Patent number: 7645741
    Abstract: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II or a salt thereof, in which R1, R2, R3, R100, R200, R300, A, A1, BG, Q and Q1 are substituents described herein. Also disclosed is the use of compounds of Formula I and II to treat proliferative disorders such as cancer.
    Type: Grant
    Filed: November 1, 2007
    Date of Patent: January 12, 2010
    Assignee: Aegera Therapeutics, Inc.
    Inventors: Alain Boudreault, James B. Jaquith, Patrick Bureau, John W. Gillard, Alain Laurent
  • Patent number: 7645742
    Abstract: A composition for enhancing cellular energy that includes creatine, L-arginine-?-ketoglutarate, D-ribose, L-carnitine, L-citrulline, and pyruvate. The composition is administering to a subject to enhance cellular energy, to increase relative intensity of physical activity performed by the subject, to increase endurance of the subject during the physical activity and to increase the muscle mass of the subject.
    Type: Grant
    Filed: June 22, 2005
    Date of Patent: January 12, 2010
    Assignee: Advocare International, L.P.
    Inventor: Sidney Stohs
  • Patent number: 7645743
    Abstract: Methods and compositions for immediately immunizing an individual against any molecule or compound. The present invention comprises an immunity linker with at least two sites; (1) at least one first binding site that binds to an immune response component in an individual that has been pre-immunized with a universal immunogen, and (2) at least one second binding site that binds specifically to a desired compound or molecule, the target.
    Type: Grant
    Filed: January 9, 2004
    Date of Patent: January 12, 2010
    Assignee: Altermune, LLC
    Inventor: Kary B. Mullis
  • Patent number: 7645744
    Abstract: RNA interference using small interfering RNAs which target HIF-1 alpha mRNA inhibit expression of the HIF-1 alpha gene. As HIF-1 alpha is a transcriptional regulator of VEGF, expression of VEGF is also inhibited. Control of VEGF production through siRNA-mediated down-regulation of HIF-1 alpha can be used to inhibit angiogenesis, in particularly in diseases such as diabetic retinopathy, age related macular degeneration and many types of cancer.
    Type: Grant
    Filed: January 26, 2009
    Date of Patent: January 12, 2010
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Samuel Jotham Reich, Enrico Maria Surace, Michael J. Tolentino
  • Patent number: 7645745
    Abstract: Compounds having the formula I wherein R1 is as herein defined are Hepatitis C virus NS5b polymerase inhibitors.
    Type: Grant
    Filed: April 4, 2007
    Date of Patent: January 12, 2010
    Assignee: Roche Palo Alto LLC
    Inventor: Keshab Sarma
  • Patent number: 7645746
    Abstract: The present invention relates to an aqueous composition for reducing malodor impression. The composition comprises from about 0.01% to about 1%, by weight of the composition, of perfume. Optionally, but preferably, the composition comprises from about 0.1% to about 5%, by weight of the composition of, water-soluble cyclodextrin, from about 0.1% to about 10%, by weight of the composition, of water-soluble metallic salt, from about 0% to about 3%, by weight of the composition, of solubilizing aid. The composition is essentially free of any material that would soil or stain fabric and contains less than about 5%, by weight of the composition of low molecular weight monohydric alcohols.
    Type: Grant
    Filed: November 13, 2000
    Date of Patent: January 12, 2010
    Assignee: The Procter & Gamble Company
    Inventors: Toan Trinh, Jerome Paul Cappel, Philip Anthony Geis, Judith Ann Hollingshead, Mark Lee McCarty, Donald Marion Swartley, Errol Hoffman Wahl, Susan Schmaedecke Zwerdling
  • Patent number: 7645747
    Abstract: The invention is related to phosphorus substituted therapeutic agents, compositions containing such phosphorus substituted agents, and therapeutic methods that include the administration of such phosphorus substituted agents, as well as to processes and intermediates useful for preparing such agents.
    Type: Grant
    Filed: October 25, 2005
    Date of Patent: January 12, 2010
    Assignee: Gilead Sciences, Inc.
    Inventors: Constantine G. Boojamra, Carina E. Cannizzaro, James M. Chen, Xiaowu Chen, Aesop Cho, Lee S. Chong, Manoj Desai, Maria Fardis, Craig S. Gibbs, Ralph F. Hirschmann, Alan X. Huang, Haolun Jin, Choung U. Kim, Thorsten A. Kirschberg, Steven Krawczyk, Christopher P. Lee, William A. Lee, Kuei-Ying Lin, Richard L. Mackman, David Y. Markevitch, Peter H. Nelson, David A. Oare, Vidya K. Prasad, Hyung-Jung Pyun, Adrian S. Ray, Rosemarie Sherlock, Sundaramoorthi Swaminathan, William J. Watkins, Jennifer R. Zhang, Lijun Zhang
  • Patent number: 7645748
    Abstract: Sterol and stanol phosphorylnitro derivatives and their use in treating or preventing cardiovascular disease, its underlying conditions and other disorders are disclosed. The disclosed compounds include a phosphate linker, at least one moiety that releases nitric oxide (NO), and a sterol or stanol moiety. Some compounds additionally include an ascorbyl moiety to make the compound more readily soluble in aqueous and non-aqueous media.
    Type: Grant
    Filed: April 3, 2006
    Date of Patent: January 12, 2010
    Assignee: Forbes Medi-Tech Inc.
    Inventors: Patricia Liliana Orchansky, James P. Kutney
  • Patent number: 7645749
    Abstract: Sterol and stanol nitro derivatives and their use in treating or preventing cardiovascular disease, its underlying conditions and other disorders are disclosed. The disclosed nitro derivatives are synthesized by ester linkage of a nitric oxide (NO)-releasing moiety to a sterol or stanol compound.
    Type: Grant
    Filed: April 3, 2006
    Date of Patent: January 12, 2010
    Assignee: Forbes Medi-Tech Inc.
    Inventors: Patricia Liliana Orchansky, James P. Kutney
  • Patent number: 7645750
    Abstract: A method for treating or preventing symptoms of hormonal variation includes administering an effective amount of a receptor antagonist to a subject having one or more symptoms of hormonal variations, wherein the receptor antagonist binds to at least one selected from the group consisting of a serotonin type 2A (5-HT2A) and a dopamine type 2 (D2) receptors.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: January 12, 2010
    Assignee: Yung Shin Pharmaceutical Ind. Co., Ltd.
    Inventor: Hung-Ming Wu
  • Patent number: 7645751
    Abstract: There is provided a compound of formula (I) wherein Ra, R1, R2, Y and R3 have meanings given in the description and pharmaceutically-acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g., thrombosis) or as anticoagulants.
    Type: Grant
    Filed: May 4, 2007
    Date of Patent: January 12, 2010
    Assignee: AstraZeneca
    Inventor: Tord Inghardt
  • Patent number: 7645752
    Abstract: The present invention is directed to compounds of Formula I: which are modulators of the 5-hydroxtryptamine-6 and 5-hydroxytryptamine-2A receptors and which are inhibitors of norepinephrine reuptake. The compounds of the invention, and pharmaceutical composition thereof, are useful in the treatment of disorders related to or associated with the 5-hydroxytryptamine-6 and 5-hydroxtryptamine-2A receptors or with norepinephrine reuptake inhibition.
    Type: Grant
    Filed: January 12, 2007
    Date of Patent: January 12, 2010
    Assignee: Wyeth LLC
    Inventors: Robert E. McDevitt, Yanfang Li, Albert J. Robichaud, Gavin D. Heffernan, Richard D. Coghlan, Ronald C. Bernotas
  • Patent number: 7645753
    Abstract: This invention is concerned with compounds of the formula wherein A, B1, B2, R1, R2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.
    Type: Grant
    Filed: March 2, 2006
    Date of Patent: January 12, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alfred Binggeli, Andreas Dominik Christ, Luke Gideon Granville Green, Wolfgang Guba, Hans-Peter Maerki, Rainer Eugen Martin, Peter Mohr
  • Patent number: 7645754
    Abstract: The subject invention provides compounds having the structure: wherein, R1 is a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(?O)NRaRb, —NRaRb, —NRaC(?O)NRaRb, —NRaC(?O)ORa, —OC(?O)NRaRb, or —NHC(?O) Ra; R2 is hydrogen or a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(?O)NRaRb, —NRaRb, —NRaC(?O)NRaRb, —NRaC(?O)ORa, —OC(?O)NRaRb, or —NHC(?O)Ra, or R1, R2 and N together form a substituted piperazine, substituted azetidine ring, or a pyrrolidine ring substituted with —(CH2)2OH or —CH2C(?O)OH; R3 is a substituted or unsubstituted phenyl or a 5-6 membered heteroaryl ring, wherein the substituent is halogen, hydroxyl, cyano, (C1-C15)alkyl, (C1-C15)alkoxy, or —NRaRb; R4 is hydrogen or substituted or unsubstituted (C1-C15)alkyl; R5 is —(CH2)mOR6, —CHNOR7, —C(?O)NR8R9, —(CH2)mC(?O)OR10, —(CH2)kC(?O)NR11R12; wherein R6 is a substituted or unsubstituted (C1-C30)alkyl, (C3-C10)cycloalkyl, or an aryl, heteroaryl
    Type: Grant
    Filed: June 19, 2007
    Date of Patent: January 12, 2010
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Arlindo Castelhano, Bryan McKibben, Arno Steinig
  • Patent number: 7645755
    Abstract: The invention is directed to compounds of Formula I: wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.
    Type: Grant
    Filed: April 20, 2006
    Date of Patent: January 12, 2010
    Assignee: Janssen Pharmaceutical N.V.
    Inventors: Carl R. Illig, Shelley K. Ballentine, Jinsheng Chen, Sanath K. Meegalla, M. Jonathan Rudolph, Mark J. Wall, Kenneth J. Wilson, Renee L. Desjarlais, Carl L. Manthey, Christopher Flores, Christopher J. Molloy
  • Patent number: 7645756
    Abstract: The invention provides a compound or its pharmaceutically-acceptable salt of formula wherein A1 is a hydrogen, etc.; j and k are 0 or 1; is a double bond, etc.; is a double bond, etc.; one of W1 and W2 is E—O—W, etc., and the other is a hydrogen atom, etc.; E is a divalent group derived from a benzene ring, etc., by removing two hydrogen atoms therefrom; W is a group of formula (II-1): which has a histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect and is useful for prevention or remedy of metabolic system diseases, circulatory system diseases or nervous system diseases.
    Type: Grant
    Filed: February 17, 2005
    Date of Patent: January 12, 2010
    Assignee: Banyu Pharmaceutical Co. Ltd.
    Inventors: Toshiyuki Takahashi, Akio Kanatani, Shigeru Tokita, Ryo Yoshimoto
  • Patent number: 7645757
    Abstract: The present invention is directed to compounds and compositions for the treatment of neurological diseases that cause neurogenic and neuropathic pain, inflammatory diseases, renal ishaemia, cardiovascular disease and other pathologies caused by the presence of endogenous cannabinoids and or other substrates resulting from the metabolic activities of fatty acid amido hydrolase (FAAH). These compounds are represented by the formula alkylene group; a salt thereof, or a hydrate or a solvate of said compound or said salt; where the variables are as defined in the attached specification.
    Type: Grant
    Filed: August 14, 2006
    Date of Patent: January 12, 2010
    Assignee: sanofi-aventis
    Inventors: Ahmed Abouabdellah, Regine Bartsch-Li, Christian Hoornaert, Antoine Ravet
  • Patent number: 7645758
    Abstract: Certain thienopyrrolyl and furanopyrrolyl compounds are disclosed as useful to treat or prevent disorders and conditions mediated by the histamine H4 receptor, including allergic rhinitis.
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: January 12, 2010
    Assignee: Janssen Pharmaceutica, N.Y.
    Inventors: Hui Cai, Nicholas I. Carruthers, Curt A. Dvorak, James P. Edwards, Annette K. Kwok, Jianmei Wei
  • Patent number: 7645759
    Abstract: Non-peptide compounds having activity as selective antagonists of bradykinin (BK) B2 receptor are disclosed. The compounds have the general formula (I) in which R is hydrogen or methyl; W is a single bond or an oxygen atom; n=3; X is hydrogen or a —NR1R2 amino group in which R1 and R2 can be independently hydrogen or a group which is methyl, ethyl, n-propyl, or isopropyl; Y is a —NR3R4R5 quaternary ammonium group in which R3, R4, R5 can be independently a group which is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or n-pentyl; and the enantiomers and enantiomeric mixtures thereof. Pharmaceutical compositions containing these compounds and methods of using the compounds to treat patients having conditions, disorders or diseases involving activation of bradykinin B2 receptors are also disclosed.
    Type: Grant
    Filed: April 10, 2007
    Date of Patent: January 12, 2010
    Assignee: Istituto Luso Farmaco D'Italia S.p.A.
    Inventors: Patrizia Felicetti, Christopher Ingo Fincham, Alessandro Giolitti, Carlo Alberto Maggi, Laura Quartara, Cristina Rossi
  • Patent number: 7645760
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the symbols have meaning as defined, which are antagonists of CCR-1 and which find use pharmaceutically for treatment of diseases and conditions in which CCR-1 is implicated, e.g. inflammatory diseases.
    Type: Grant
    Filed: October 24, 2003
    Date of Patent: January 12, 2010
    Assignee: Novartis AG.
    Inventors: Birgit Bollbuck, Jorg Eder, Richard Heng, Laszio Revesz, Achim Schlapbach, Rudolf Walchli
  • Patent number: 7645761
    Abstract: This invention relates to substituted indoline derivative compounds which are antagonists of the progesterone receptor, their preparation and pharmaceutical utility, particularly including contraception and treatment of benign or malignant neoplastic diseases, having the general structure: wherein R1 and R2 may be single substituents or fused to form spirocyclic rings.
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: January 12, 2010
    Assignee: Wyeth
    Inventors: Andrew Fensome, Lori L. Miller, John W. Ullrich, Reinhold H. W. Bender, Puwen Zhang, Jay E. Wrobel, Lin Zhi, Todd K. Jones, James P. Edwards, Christopher M. Tegley
  • Patent number: 7645762
    Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: January 12, 2010
    Assignee: Schering Corporation
    Inventors: Kamil Paruch, Timothy J. Guzi, Michael P. Dwyer
  • Patent number: 7645763
    Abstract: The present invention relates to substituted xanthines of general formula wherein R1 and R2 are defined as in the claims, the tautomers, the stereoisomers, the mixtures thereof, and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Grant
    Filed: February 22, 2005
    Date of Patent: January 12, 2010
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Frank Himmelsbach, Elke Langkopf, Matthias Eckhardt, Mohammad Tadayyon, Leo Thomas
  • Patent number: 7645764
    Abstract: Compounds of formula I: wherein R1, R2, R3 and R4 are as defined herein. Also disclosed are methods of making the compounds, pharmaceutical compositions, methods of using the compounds for treatment of p38 MAP kinase-mediated diseases, and methods of using the compounds for treatment of Raf kinase-mediated diseases.
    Type: Grant
    Filed: November 8, 2007
    Date of Patent: January 12, 2010
    Assignee: Roche Palo Alto LLC
    Inventors: Tobias Gabriel, Joel McIntosh, Kin-Chun Thomas Luk
  • Patent number: 7645765
    Abstract: The invention relates to a drug containing an aqueous formulation of Moxaverin and at least one water-miscible solubilizer.
    Type: Grant
    Filed: September 2, 2002
    Date of Patent: January 12, 2010
    Assignee: Molecular and Clinical Drug Research
    Inventor: Ralph E. Eckert
  • Patent number: 7645766
    Abstract: A method for treatment of depression and depressive mood disorders. The patient is administered an amount of a compound that increases the catalytic activity of MAO-A, so as to increase synaptic metabolism of serotonin to 5-HIAL. The effective compound is preferably reserpine, administered in a dosage of less than about 0.03 mg per day. The reserpine may be administered transdermally at a dosage in the range from about 0.002 mg per day to about 0.02 mg per day. A caffeine compound may be administered simultaneously so as to compensate for an antihypertensive effect of the reserpine. The caffeine compound may be combined with the reserpine in a transdermal cream.
    Type: Grant
    Filed: September 20, 2005
    Date of Patent: January 12, 2010
    Assignee: MedDEV, Inc.
    Inventor: Elaine A. Delack
  • Patent number: 7645767
    Abstract: Chronic pain is alleviated in a mammal suffering there from by administering to the mammal a chronic pain alleviating amount of a nontoxic N-methyl-D-aspartate receptor antagonist such as dextromethorphan, dextrorphan, ketamine or pharmaceutically acceptable salt thereof, in combination with a ?-opiate analgesic such as tramadol or an analogously acting molecular entity, and a capsaicin or an ester of capsaicin, and optionally in sustained release dosage form.
    Type: Grant
    Filed: August 22, 2007
    Date of Patent: January 12, 2010
    Assignee: Trinity Laboratories, Inc.
    Inventors: Chandra Ulagaraj Singh, David Lloyd Woody, Jagaveerabhadra Rao Nulu
  • Patent number: 7645768
    Abstract: The present invention relates to production of polyketides and other natural products and to libraries of compounds and individual novel compounds. One important area is the isolation and potential use of novel FKBP-ligand analogues and host cells that produce these compounds. The invention is particularly concerned with methods for the efficient transformation of strains that produce FKBP analogues and recombinant cells in which cloned genes or gene cassettes are expressed to generate novel compounds such as polyketide (especially rapamycin) FKBP-ligand analogues, and to processes for their preparation, and to means employed therein (e.g. nucleic acids, vectors, gene cassettes and genetically modified strains).
    Type: Grant
    Filed: July 16, 2007
    Date of Patent: January 12, 2010
    Assignee: Wyeth
    Inventors: Matthew Alan Gregory, Sabine Gaisser, Hrvoje Petkovic, Steven Moss
  • Patent number: 7645769
    Abstract: The present invention provides novel compounds of formula I and their use in the inhibition of c-Jun N-terminal kinases. The present invention further provides the use of these compounds in medicine, in particular in the prevention and/or treatment of neurodegenerative disorders related to apoptosis and/or inflammation.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: January 12, 2010
    Assignee: Eisai R & D Management Co., Ltd.
    Inventors: Afzal Khan, Darren Peter Medland, Gurpreet Singh Bhatia
  • Patent number: 7645770
    Abstract: Phenylalanine enamide derivatives of formula (1) are described: wherein R1 is a group Ar1L2Ar2Alk- in which: Ar1 is an optionally substituted aromatic or heteroaromatic group; L2 is a covalent bond or a linker atom or group; Ar2 is an optionally substituted arylene or heteroarylene group; and Alk is a chain —CH2—CH(R)—, —CH?C(R)— or in which R is a carboxylic acid (—CO2H) or a derivative or biostere thereof; X is an —O— or —S— atom or —N(R2)— group in which: Rx, Ry and Rz which may be the same or different is each a hydrogen atom or an optional substituent; or Rz is an atom or group as previously defined and Rx and Ry are joined together to form an optionally substituted spiro linked cycloaliphatic or heterocycloaliphatic group; and the salts, solvates, hydrates and N-oxides thereof.
    Type: Grant
    Filed: December 3, 2008
    Date of Patent: January 12, 2010
    Assignee: UCB Pharma S.A.
    Inventors: Stephen Brand, Stuart Bailey, Julien A. Brown, James A. Johnson, John R. Porter, John C. Head
  • Patent number: 7645771
    Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable derivatives thereof, useful in the treatment of prophylazis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: January 12, 2010
    Assignee: SmithKline Beecham Corp.
    Inventors: Wieslaw Mieczyslaw Kazmierski, Chrisopher Joseph Aquino, Neil Bifulco, Eric Eugene Boros, Brian Andrew Chauder, Pek Yoke Chong, Maosheng Duan, Felix Deanda, Jr., Cecilia Suarez Koble, Ed Williams McLean, Jennifer Poole Peckham, Angilique C Perkins, James Benjamin Thompson, Dana Vanderwall
  • Patent number: 7645772
    Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
    Type: Grant
    Filed: October 28, 2003
    Date of Patent: January 12, 2010
    Assignee: Wellstat Therapeutics Corporation
    Inventors: Kirvin L. Hodge, Shalini Sharma, Reid W. von Borstel, Stephen D. Wolpe
  • Patent number: 7645773
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.
    Type: Grant
    Filed: January 8, 2007
    Date of Patent: January 12, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Paul Gillespie, Robert Alan Goodnow, Jr., Agnieszka Kowalczyk, Kang Le, Qiang Zhang
  • Patent number: 7645774
    Abstract: There are disclosed compounds of the formula I: or a pharmaceutically acceptable salt of the compound, which exhibit anti-inflammatory and immunomodulatory activity. Also disclosed are pharmaceutical compositions containing said compounds.
    Type: Grant
    Filed: August 5, 2005
    Date of Patent: January 12, 2010
    Assignee: Schering Corporation
    Inventors: Richard J. Friary, Joseph A. Kozlowski, Bandarpalle B. Shankar, Michael K. C. Wong, Guowei Zhou, Brian J. Lavey, Neng-Yang Shih, Ling Tong, Lei Chen, Youheng Shu
  • Patent number: 7645775
    Abstract: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: October 21, 2005
    Date of Patent: January 12, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Robert Davies, Cornelia Forster, Michael Arnost, Jian Wang
  • Patent number: 7645776
    Abstract: The invention is concerned with novel substituted piperidine derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and X are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.
    Type: Grant
    Filed: November 29, 2006
    Date of Patent: January 12, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jean Ackermann, Konrad Bleicher, Simona M. Ceccarelli Grenz, Odile Chomienne, Patrizio Mattei, Tanja Schulz-Gasch
  • Patent number: 7645777
    Abstract: A switching device is discloses that exhibits two stable resistance values to a voltage applied between electrodes. The switching device comprises thin films of a first electrode layer, an organic bistable material layer and a second electrode layer sequentially formed on a substrate, and the organic bistable material is a specified quinone compound.
    Type: Grant
    Filed: November 20, 2006
    Date of Patent: January 12, 2010
    Assignee: Fuji Electric Holdings Co., Ltd.
    Inventors: Nobuyuki Sekine, Haruo Kawakami, Hisato Kato, Keisuke Yamashiro, Kyoko Kato, Masami Kuroda
  • Patent number: 7645778
    Abstract: The present invention provides novel heteroaryl compounds and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.
    Type: Grant
    Filed: January 17, 2006
    Date of Patent: January 12, 2010
    Assignee: Bristol-Myers Squibb COmpany
    Inventors: James C. Sutton, Zulan Pi, Rejean Ruel, Alexandre L'Heureux, Carl Thibault, Patrick Y. S. Lam
  • Patent number: 7645779
    Abstract: Compounds, compositions and methods that are useful for the treatment of metabolic disorders, inflammatory diseases and cancer are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in lipid metabolism, inflammation and cell proliferation. The subject compounds are linked biaryl compounds.
    Type: Grant
    Filed: August 20, 2004
    Date of Patent: January 12, 2010
    Assignees: Amgen Inc., Japan Tobacco, Inc.
    Inventors: Hiroyuki Abe, Jonathan Houze, Hisashi Kawasaki, Frank Kayser, Rajiv Sharma, Samuel Sperry
  • Patent number: 7645780
    Abstract: Disclosed are compounds of the formula: where variables Z, X, R15, R2, R3, and Rc are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal.
    Type: Grant
    Filed: June 6, 2006
    Date of Patent: January 12, 2010
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Varghese John, Michel Maillard, James P. Beck, Eric T. Baldwin, Robert Hughes, Shon R. Pulley, Ruth T. TenBrink
  • Patent number: 7645781
    Abstract: The present invention provides antibacterial agents having the formulae I, II, and III described herein.
    Type: Grant
    Filed: September 21, 2006
    Date of Patent: January 12, 2010
    Assignee: Pfizer Inc
    Inventors: Richard C. Thomas, Toni-Jo Poel, Michael R. Barbachyn, Mikhail F. Gordeev, Gary W. Luehr, Adam Renslo, Upinder Singh, Vara Prasad Venkata Negandra Josyula
  • Patent number: 7645782
    Abstract: The present invention relates to new Macrocycles of formula (I) and their use for the treatment of cancer.
    Type: Grant
    Filed: November 28, 2003
    Date of Patent: January 12, 2010
    Assignees: Morphochem Aktiengesellschaft fur Kombinatorische Chemie
    Inventors: Wolfgang Richter, Lutz Weber
  • Patent number: 7645783
    Abstract: A method of treating viral infections by the administration of a halogenated benzamide derivative according to formula (III): in which R1 is a halogen atom, and R2-R6 are independently hydrogen, hydroxyl, C1-C4 alkyl, —C1-C4 alkoxy, acyloxy, nitro, halogen, —C(O)R7 where R7 is —C1-C4 alkyl, or, aromatic including salts and hydrates of these compounds.
    Type: Grant
    Filed: October 1, 2007
    Date of Patent: January 12, 2010
    Assignee: Romark Laboratories L.C.
    Inventor: Jean Francois Rossignol
  • Patent number: 7645784
    Abstract: Compounds of formula I, wherein R1, m, R2, R3, p, n, R5 and R9 are as defined as in the specification, salts, solvates or solvated salts thereof, processes for their preparation, intermediates used in the preparation thereof, pharmaceutical formulations containing said compounds and the use of said compounds in therapy.
    Type: Grant
    Filed: May 13, 2004
    Date of Patent: January 12, 2010
    Assignee: AstraZeneca AB
    Inventors: Yevgeni Besidski, Inger Kers, Martin Nylöf, Didier Rotticci, Andis Slaitas, Mats Svensson
  • Patent number: 7645785
    Abstract: The invention is concerned with novel benzimidazole derivatives of formula (I) wherein R1 to R8 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to Farnesoid-X-receptors (FXR) and can be used to treat diseases which are modulated by FXR agonists such as diabetes and dyslipidemia.
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: January 12, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Gregory Martin Benson, Konrad Bleicher, Alexander Chucholowski, Henrietta Dehmlow, Uwe Grether, Bernd Kuhn, Rainer E. Martin, Eric J. Niesor, Narendra Panday, Hans Richter, Franz Schuler, Xavier Marie Warot, Matthew Wright, Minmin Yang
  • Patent number: 7645786
    Abstract: This invention relates to a range of 1-aryl-4-cyclopropylpyrazoles in which the cyclopropyl ring is substituted at the angular position, and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes to their synthesis and their use as parasiticides.
    Type: Grant
    Filed: December 14, 2006
    Date of Patent: January 12, 2010
    Assignee: Pfizer Inc.
    Inventors: Denis Billen, Jessica Boyle, Douglas James Critcher, David Morris Gethin, Kim Thomas Hall, Graham Michael Kyne
  • Patent number: 7645787
    Abstract: The present invention provides pyrazole-O-glycoside derivatives represented by the following formulae, used as a diabetic medicine.
    Type: Grant
    Filed: July 6, 2007
    Date of Patent: January 12, 2010
    Assignee: Ajinomoto Co., Inc.
    Inventors: Koji Ohsumi, Takashi Umemura, Hiroyuki Matsueda, Toshihiro Hatanaka, Akiko Onuki, Katsumi Maezono, Yoko Kageyama, Nobuo Kondo
  • Patent number: 7645788
    Abstract: Use of the tetramerous derivative of indole-3-carbinol having formula I for preparing a medicinal having anti-carcinogenic activity, and method of synthesis of the tetramerous derivative having formula I, in which indole-3-carbinol is reacted with an oxidizing agent so as to cause a polymeric oxidation of indole-3-carbinol.
    Type: Grant
    Filed: June 5, 2002
    Date of Patent: January 12, 2010
    Assignee: Universita' Degli Studi Di Urbino
    Inventors: Mauro Magnani, Chiara Fiorucci, Paolino Filippone, Giorgio Brandi, Mirko Paiardini
  • Patent number: 7645789
    Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: January 12, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Sara S. Hadida Ruah, Peter D. J. Grootenhuis, Fredrick Van Goor, Jinglan Zhou, Brian Bear, Mark T. Miller, Jason McCartney, Mehdi Michel Djamel Numa
  • Patent number: 7645790
    Abstract: The present invention is directed to certain hydroisoindoline compounds of formula I which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.
    Type: Grant
    Filed: January 26, 2005
    Date of Patent: January 12, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jaime Lynn Bunda, Robert J. DeVita, Jinlong Jiang, Sander G. Mills